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Introduction
Over the years, several vaccines have been developed to pro-
tect children from rotaviruses, the leading cause of severe diar-
rhea in children less than 5 years of age. Two rotavirus vaccines 
have now been licensed in many parts of the world: a pentava-
lent live human-bovine reassortant vaccine (RotaTeq, rotavirus 
vaccine, live, oral, pentavalent; Merck, Whitehouse Station, 
New Jersey, US; designated RV5 by the Advisory Committee 
on Immunization Practices [ACIP]1) and a live, attenuated 
G1P1A[8] human rotavirus vaccine (Rotarix, GlaxoSmithKline 
Biologicals, Rixensart, Belgium; designated RV1 by the ACIP1).
The efficacy of RV5 following receipt of the recommended 
3-dose series was evaluated in the Rotavirus Efficacy and Safety 
Trial (REST) in 2 ways: (1) reduction in the rates of rotavirus 
post-hoc analyses of the Rotavirus efficacy and safety Trial (ResT) were conducted to determine whether the pentavalent 
rotavirus vaccine (RV5) confers early protection against rotavirus gastroenteritis (RVGe) before completion of the 3-dose 
regimen. To evaluate the efficacy of RV5 between doses in reducing the rates of RVGe-related hospitalizations and 
emergency department (eD) visits in infants who ultimately received all 3 doses of RV5/placebo, events occurring from 
two weeks after the first and second doses to receipt of the subsequent dose (analysis a) and events occurring from two 
weeks after the first and second doses to two weeks after the subsequent dose (analysis B) were analyzed. In analysis a, 
RV5 reduced the rates of combined hospitalizations and eD visits for G1–G4 RVGe or RVGe regardless of serotype between 
doses 1 and 2 by 100% [95% confidence interval (cI): 72–100%] or 82% (95% cI: 39–97%), respectively, and between doses 
2 and 3, RV5 reduced the rates of combined hospitalizations and eD visits for G1–G4 RVGe or RVGe regardless of serotype 
by 91% (95% cI: 63–99%) or 84% (95% cI: 54–96%), respectively. similar rate reductions were observed in analysis B. 
These data suggest that RV5 provides a high level of protection between doses against hospitalizations and eD visits for 
RVGe starting as early as 14 days after the first dose.
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gastroenteritis (RVGE) hospitalizations and emergency depart-
ment (ED) visits; and (2) prevention of RVGE cases.2,3 In REST, 
the rate of RVGE hospitalizations and ED visits caused by G1–
G4 rotaviruses was reduced by 95% (95% confidence interval 
[CI]: 91–97%) by RV5 through up to 2 years after completion 
of the vaccination schedule. The rate of RVGE hospitalizations 
and ED visits caused by rotaviruses of any serotype was also 
reduced by 95% (95% CI: 92–97%) by RV5. In REST, enroll-
ment occurred year round and the per-protocol analyses were 
based on follow-up beginning 14 days after the third dose. In this 
paper, post-hoc analyses of REST were conducted to determine 
whether RV5 confers protection to infants before completion of 
the 3-dose regimen. These analyses may be of particular interest 
to health care professionals immunizing infants during, or just 
prior to, the rotavirus season.
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combined hospitalizations and ED visits due to RVGE regardless 
of serotype was 82% (95% CI: 39–97%) between doses 1 and 2 
and 84% (95% CI: 54–96%) between doses 2 and 3 (Table 2). 
Among vaccine recipients, there were 7 health care encounters, 
3 between doses 1 and 2 and 4 between doses 2 and 3; 1 of the 
health care encounters was a hospitalization. Among placebo 
recipients, there were 42 health care encounters, 17 between 
doses 1 and 2 and 25 between doses 2 and 3; 18 of the 42 health 
care encounters were hospitalizations. The reduction in the rate 
of combined hospitalizations and ED visits was slightly greater 
in Analysis B (Table 2). Two additional RVGE-related health 
care encounters among the vaccine recipients (1 between doses 1 
and 2 and 1 between doses 2 and 3) and 31 among the placebo 
recipients (15 between doses 1 and 2 and 16 between doses 2 
and 3) were captured in Analysis B. Among the vaccine recipi-
ents, none of the additional health care encounters were hospital-
izations. Among placebo recipients, 16 of the 31 additional health 
care encounters were hospitalizations. Overall, vaccine efficacy 
against RVGE hospitalizations between doses ranged from 90% 
to 100%. G1 was the most common serotype identified (detailed 
breakdown provided in footnote, Table 2).
Efficacy of RV5 against RVGE-related health care encoun-
ters among the subset of infants who received less than 3 doses 
(incomplete regimen). Subject compliance in REST was high, 
with 59,210 infants (86%) having received 3 doses of RV5 or pla-
cebo.2 In REST, among infants who received only 1 dose or only 
2 doses, the number of health care encounters was small, and the 
rate reductions in RVGE-associated combined hospitalizations 
and ED visits were not statistically significant.
Results
Efficacy between doses against health care encounters attribut-
able to G1–G4 RVGE in infants who received all 3 doses. In 
Analysis A, the reduction in the rate of combined hospitaliza-
tions and ED visits for G1–G4 RVGE between doses 1 and 2 
was 100% (95% CI: 72–100%) and between doses 2 and 3 was 
91% (95% CI: 63–99%) (Table 1). There were only 2 RVGE-
associated health care encounters among vaccine recipients, and 
both encounters were ED visits that occurred between doses 2 
and 3. In contrast, there were 37 RVGE-associated health care 
encounters among placebo recipients: 15 between doses 1 and 
2 and 22 between doses 2 and 3. Sixteen of the 37 health care 
encounters were hospitalizations. Although Analysis B extended 
the follow-up interval, the reduction in the rate of combined hos-
pitalizations and ED visits for G1–G4 RVGE was identical to that 
of Analysis A [100% between doses 1 and 2 and 91% between 
doses 2 and 3, with small changes to the CIs (Table 1)]. Only 
1 additional RVGE-associated health care encounter, an ED 
visit between doses 2 and 3, was observed in the vaccine group, 
whereas 26 additional encounters were observed in the placebo 
group, 14 between doses 1 and 2 and 12 between doses 2 and 3. 
Under both analysis strategies, vaccine efficacy against G1–G4 
RVGE hospitalizations was 100% between doses. Overall, G1 
was the most common serotype identified (detailed breakdown 
provided in footnote, Table 1).
Efficacy between doses against health care encounters 
attributable to RVGE regardless of serotype in infants who 
received all 3 doses. In Analysis A, the reduction in the rate of 
Table 1. Rate reduction in RVGe-related health care encounters (hospitalizations and eD visits) between vaccine dosesa attributable to G1–G4 
 rotavirus
G1–G4 RVGEb Interval (N) Health care encounter Vaccine Placebo Efficacy (%) 95% CI (%)
Counts (n)/evaluable (n)
analysis ac Doses 1 to 2 (58,851) Hospitalizations 0/29,417 6/29,434 100 15–100
eD visits 0/29,417 9/29,434 100 49–100
combined hospital and eD visits 0/29,417 15/29,434 100 72–100
Doses 2 to 3 (59,061) Hospitalizations 0/29,496 10/29,565 100 55–100
eD visits 2/29,496 12/29,565 83 25–98
combined hospital and eD visits 2/29,496 22/29,565 91 63–99
analysis Bd Doses 1 to 2 (58,851) Hospitalizations 0/29,413 12/29,438 100 64–100
eD visits 0/29,413 17/29,438 100 76–100
combined hospital and eD visits 0/29,413 29/29,438 100 87–100
Doses 2 to 3 (59,019) Hospitalizations 0/29,473 18/29,546 100 77–100
eD visits 3/29,473 16/29,546 81 34–97
combined hospital and eD visits 3/29,473 34/29,546 91 72–98
N, number of evaluable infants who received 3 doses of vaccine or placebo; RVGe, rotavirus gastroenteritis; cI, confidence interval; eD, emergency 
department. aGiven that the interval between doses was to be 4–10 weeks, the range of follow up was 14–56 days per infant in analysis a and 14–69 
days per infant in analysis B. bThe most common rotavirus serotype identified was G1, followed by a few samples that contained G2, G4, and G3 rota-
virus strains. Between doses 1 and 2 among placebo recipients, the distribution of the rotavirus serotypes in the total number (n = 29) of RVGe-related 
health care encounters in analysis B, which also includes the 15 health care encounters in analysis a, was G1 (n = 22), G2 (n = 4), G3 (n = 1), and G4  
(n = 2). Between doses 2 and 3, the distribution of the rotavirus serotypes in the total number (n = 34) of RVGe-related health care encounters in analy-
sis B, which also includes the 22 health care encounters in analysis a, among vaccine recipients was G1 (n = 3) and among placebo recipients was G1  
(n = 31) and G3 (n = 3). canalysis a: ≥14 days post dose 1 (pD1) up to dose 2 and ≥14 days pD2 up to dose 3. danalysis B: ≥14 days pD1 through 13 days 
pD2 and from ≥14 days pD2 through 13 days pD3.
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Discussion
In REST, both the safety and efficacy of the complete regimen of 
RV5 were demonstrated in nearly 70,000 infants.2 The prespeci-
fied time frame to measure the efficacy of RV5 in reducing the 
rate of RVGE-associated health care encounters (i.e., hospitaliza-
tions and ED visits) in REST started 14 days after completion of 
the 3-dose regimen. Given that many infants are routinely vac-
cinated during the season when rotavirus is circulating and risk 
of illness is greatest, post-hoc analyses were conducted to evalu-
ate the efficacy of RV5 before completion of the 3-dose regimen. 
Although REST was not designed or powered to examine the 
efficacy between doses, vaccine efficacy between doses among 
infants who ultimately completed the 3-dose vaccination sched-
ule was retrospectively examined. A separate analysis among the 
small number of infants who received only 1 dose or only 2 doses 
of vaccine in REST also was conducted.
In the post-hoc analyses of infants who completed the 3-dose 
regimen, a high level of protection against RVGE-related hospi-
talizations and ED visits combined caused by serotypes G1–G4 
and rotavirus of any serotype between doses was demonstrated 
by RV5. Vaccine efficacy against G1–G4 RVGE-related hospi-
talizations and ED visits was 100% between doses 1 and 2 and 
91% between doses 2 and 3 regardless of whether the analysis 
time frame ended at the subsequent dose or 13 days after the sub-
sequent dose. Similarly, vaccine efficacy against hospitalizations 
Among infants who received only 1 dose of RV5/placebo, 
the number of health care encounters was small for the G1–G4 
RVGE analysis (RV5, 3 G1-related events; placebo, 6 G1-related 
events) and the RVGE of any serotype analysis [RV5, 6 events 
(3 G1-related, 1 G9-related and 2 nontypeable); placebo, 7 events 
(6 G1-related and 1 nontypeable)]. Among the 5,408 evaluable 
infants who received only 1 dose (2,738 in the RV5 group and 
2,670 in the placebo group), the rate reduction in combined hos-
pitalizations and ED visits for G1–G4 RVGE was 52% (95% CI: 
<0–92%). The rate reduction in combined hospitalizations and 
ED visits for RVGE of any serotype among the 5,409 evaluable 
infants who received only 1 dose (2,738 in the RV5 group and 
2,671 in the placebo group) was 18% (95% CI: <0–75%).
Similarly, among infants who received only 2 doses of RV5/
placebo, the number of health care encounters was also small for 
the G1–G4 RVGE analysis (RV5, 1 G3-related event; placebo, 
3 G1-related events) and the RVGE of any serotype analysis 
[RV5, 1 G3-related event; placebo, 4 events (3 G1-related and 
1 G9-related)]. Among the 2,457 evaluable infants who received 
only 2 doses (1,202 in the RV5 group and 1,255 in the placebo 
group), the rate reduction in combined hospitalizations and ED 
visits for G1–G4 RVGE was 64% (95% CI: <0–99%), whereas 
the rate reduction in combined hospitalizations and ED visits for 
RVGE of any serotype among the 2,456 evaluable infants who 
received only 2 doses (1,202 in the RV5 group and 1,254 in the 
placebo group) was 73% (95% CI: <0–100%).
Table 2. Rate reduction in RVGe-related health care encounters (hospitalizations and eD visits) between vaccine dosesa attributable to rotavirus  
of any serotype
RVGE of any 
serotypeb
Interval (N) Health care encounter Vaccine Placebo Efficacy (%) 95% CI (%)
Counts (n)/evaluable (n)
analysis ac Doses 1 to 2 (58,856) Hospitalizations 0/29,422 8/29,434 100 42–100
eD visits 3/29,422 9/29,434 67 <0–94*
combined hospital and eD visits 3/29,422 17/29,434 82 39–97
Doses 2 to 3 (59,064) Hospitalizations 1/29,497 10/29,567 90 30–100
eD visits 3/29,497 15/29,567 80 29–96
combined hospital and eD visits 4/29,497 25/29,567 84 54–96
analysis Bd Doses 1 to 2 (58,858) Hospitalizations 0/29,420 15/29,438 100 72–100
eD visits 4/29,420 17/29,438 76 28–94
combined hospital and eD visits 4/29,420 32/29,438 88 65–97
Doses 2 to 3 (59,033) Hospitalizations 1/29,484 19/29,549 95 67–100
eD visits 4/29,484 22/29,549 82 46–95
combined hospital and eD visits 5/29,484 41/29,549 88 69–96
N, number of evaluable infants who received 3 doses of vaccine or placebo; RVGe, rotavirus gastroenteritis; cI, confidence interval; eD, emergency 
department. *Not statistically significant. aGiven that the interval between doses was to be 4–10 weeks, the range of follow up was 14–56 days per 
infant in analysis a and 14–69 days per infant in analysis B. bIn addition to rotavirus serotypes G1 to G4, between doses 1 and 2, 4 nontypeable and 
3 G9 RVGe-related health care encounters were detected among vaccine and placebo recipients, respectively. Between doses 2 and 3, G9 (n = 3), G8 
(n = 1), G10 (n = 1), and nontypeable (n = 2) RVGe-related health care encounters were also detected among placebo recipients, whereas 2 additional 
nontypeable RVGe-related health care encounters were detected among vaccine recipients. canalysis a: ≥14 days post dose 1 (pD1) up to dose 2 and 
≥14 days pD2 up to dose 3. danalysis B: ≥14 days pD1 through 13 days pD2 and from ≥14 days pD2 through 13 days pD3.
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Control and Prevention designed to evaluate the impact of new 
vaccines at several sites in the US.11 Based upon data from the 
2007 and 2008 rotavirus seasons, their results showed that 1, 2 
and 3 doses of RV5 were 71% (95% CI: 17–90%), 72% (95% 
CI: 1–92%) and 88% (95% CI: 47–97%), respectively, effec-
tive at preventing RVGE-related ED visits and hospitalizations. A 
consistent pattern of reduction of all-cause and rotavirus-related 
gastroenteritis has been repeatedly observed after introduction of 
RV5. These significant reductions have been observed in other 
postlicensure disease surveillance and effectiveness studies in the 
US12-14 and other countries that have introduced RV5 into their 
childhood immunization schedules.14-19
Conclusions. RV5 is a 3-dose vaccine that protects infants 
against RVGE. RV5 provided a high level of protection between 
doses against hospitalizations and ED visits for RVGE starting 
as early as 14 days after the first dose. This may be particularly 
beneficial to infants being immunized during, or just prior to, the 
rotavirus season.
Patients and Methods
Study design. REST was a large-scale, placebo-controlled, mul-
ticenter, randomized clinical trial that enrolled nearly 70,000 
infants year round.2,3,20 Healthy infants between 6 and 12 weeks 
of age at dose 1 were randomized 1:1 to receive 3 oral doses of 
RV5 or placebo as outlined in Figure 1A.
Post-hoc analyses. Efficacy between doses of RV5, as measured 
by a reduction in the rate of RVGE-related health care encoun-
ters, including hospitalizations and ED visits, among infants who 
received all 3 doses of RV5 or placebo was evaluated to examine 
whether the vaccine confers early protection before completion of 
the 3-dose regimen (Fig. 1B). The efficacy of RV5 for infants who 
received only 1 dose or only 2 doses of vaccine or placebo was also 
evaluated (Fig. 1B). RVGE was defined exactly as it was in REST.2 
Reverse transcription polymerase chain reaction and sequencing 
was used to genotype all rotavirus-positive stool samples.2 In REST, 
the per-protocol measures of efficacy were assessed beginning 14 
days post-dose (PD) 3 to allow time for an immune response to the 
last dose to develop (Fig. 1A) and a consistent approach was used 
for the between-dose and less-than-3-dose analyses.
Among infants who completed the 3-dose vaccination series 
and were not protocol violators (i.e., per-protocol population), vac-
cine efficacy between doses was measured using 2 analyses that dif-
fered with regard to the time interval used: (1) Analysis A, defined 
as ≥14 days PD1 up to dose 2 and ≥14 days PD2 up to dose 3; and 
(2) Analysis B, defined as ≥14 days PD1 through 13 days PD2 and 
from ≥14 days PD2 through 13 days PD3 (Fig. 1B). In both analy-
ses, 14 days PD1 or PD2 was used as the starting point to allow time 
for an immune response to develop, consistent with the time frame 
used to evaluate the per-protocol efficacy of the vaccine.2 However, 
in Analysis B, the analysis interval extended 13 days beyond the 
next dose to capture any RVGE-related events occurring before 
the effect of an immune response to the subsequent dose might be 
expected. The interval between doses was to be 4 to 10 weeks, and 
the follow-up times for the analyses of efficacy started and ended at 
the indicated time intervals (Fig. 1B). In addition, vaccine efficacy 
and ED visits for RVGE of any serotype was 82% to 88% 
between doses 1 and 2 and 84% to 88% between doses 2 and 3. 
Based on the vaccine schedule, these data suggest the potential 
for RV5 to provide high efficacy and rapid protection in young 
infants during the immunization schedule. Between doses, vac-
cine efficacy against hospitalizations alone was 100% for G1–G4 
RVGE and 90% to 100% for RVGE caused by any serotype. 
These results may be of interest because rotavirus-related health 
care encounters can occur in young infants. In the era before uni-
versal vacccination in the US, 17% of rotavirus hospitalizations 
occurred in infants less than 6 months of age.4 Circumstances in 
Europe may be similar to those in the US,5 although variation 
among European countries exists.6,7
The efficacy between doses of RV1, whose complete vaccine 
regimen consists of 2 doses, against RVGE was evaluated in a 
European Phase III study that enrolled over 4,000 infants. From 
the day of dose 1 up until dose 2, vaccine efficacy was 100% (95% 
CI: <0–100%) against severe RVGE and 90% (95% CI: 9–100%) 
against RVGE of any severity.8,9 In a larger Phase III study that 
enrolled infants from Latin America and Finland, the efficacy of 
RV1 against severe RVGE in the Latin American cohort was 51% 
between doses 1 and 2 and 61% from dose 1 until 14 days after 
dose 2, with wide CIs given the small number of cases.9 Because 
the trials for the two vaccines were conducted differently, the 
results between the trials can not be directly compared.
With respect to infants who received only 1 dose or only 
2 doses of RV5 or placebo, the number of RVGE-related health 
care encounters observed was small. Although the estimates were 
positive, the efficacy was not statistically significant in either eval-
uation. However, higher protection against RVGE-attributable 
health care encounters was generally provided by 2 doses than 
by only 1 dose.
The efficacy against RVGE cases of any severity, which was 
measured in the clinical efficacy substudy of REST, was analyzed 
in a similar manner as the efficacy between doses and after only 1 
dose or only 2 doses against RVGE-related health care encounters. 
The cohort in the clinical efficacy substudy was less than one-tenth 
the entire size of REST and the efficacy outcomes in these evalu-
ations were generally not statistically significant (data not shown).
Although some protection is likely conferred with less than 
3 doses of RV5, only the complete 3-dose vaccine series was 
prospectively studied in Phase III trials and may provide more 
durable and optimal protection. Because REST was not designed 
to evaluate the efficacy of RV5 with less than 3 doses, conclusions 
drawn from these analyses should be interpreted cautiously.
However, the effectiveness of partial vaccination with RV5 has 
been evaluated since licensure in routine clinical use in the US.10 
Fecal specimens from children with acute gastroenteritis 15 days 
to 23 months of age were collected over a 5-month period. One, 
2 and 3 doses of RV5, respectively, were 69% (95% CI: 13–89%), 
81% (95% CI: 13–96%) and 88% (95% CI: 68–96%) effective 
at preventing ED visits or hospitalizations from rotavirus disease 
when children with acute respiratory infection and rotavirus neg-
ative gastroenteritis were used as the combined control group.10 
Similar findings were observed by the New Vaccine Surveillance 
Network, a program coordinated by the US Centers for Disease 
©2011 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Human Vaccines 567
as the analysis technique used in REST,2 with the exception that 
exact methodology was used rather than the generalized esti-
mating equations (GEE), because GEE is not optimal in small 
samples.
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